Aminex Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aminextx.com
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1
Terminated
- Conditions
- Advanced CancerDIPG Brain TumorOvary CancerMesotheliomas PleuralPapillary Thyroid CancerGastric CancerMesothelioma PeritoneumCancerNsclcCervical Cancer
- Interventions
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Aminex Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05500508
- Locations
- 🇺🇸
Mayo Clinic - Minnesota, Rochester, Minnesota, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Mayo Clinic - Florida, Jacksonville, Florida, United States
Oral AMXT 1501 Dicaprate in Combination With DFMO
Phase 1
Completed
- Conditions
- Advanced CancerCancerSolid CarcinomaSolid Tumor
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Aminex Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03536728
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Next Oncology - San Antonio, San Antonio, Texas, United States
🇺🇸Virginia Cancer Center, Fairfax, Virginia, United States
Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers
Phase 1
Withdrawn
- Conditions
- ToleranceNeoplasmsMedication Toxicity
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Aminex Therapeutics, Inc.
- Registration Number
- NCT03077477
- Locations
- 🇺🇸
IQVIA (formerly Quintiles IMS), Overland Park, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath